Compare Cassava Sciences Inc (FLNA) vs Hafnia Limited Common Shares (HAFN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Hafnia Limited Common Shares — how do they compare? Cassava Sciences Inc trades at $0.71 (market cap $35.34M), while Hafnia Limited Common Shares trades at $10.13 (market cap $5.67B). The key difference: Hafnia Limited Common Shares is far larger — about 160.4× Cassava Sciences Inc's market cap, and Hafnia Limited Common Shares pays a 10.44% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 38 Days and Hafnia Limited Common Shares for 0 Days on average.
| FLNA | HAFN | |
|---|---|---|
Market Cap | $35.34M | $5.67B |
Volume | 251,946 | 3,240,007 |
Sector | Health | Industrials |
52-Week High | $4.64 | $10.92 |
52-Week Low | $0.68 | $5.21 |
Typical Hold Time | 38 Days | 0 Days |
Enterprise Value | -$47.34M | $6.29B |
Dividend Yield | — | 10.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.7434, down 3.39% today, with a bearish technical signal despite oscillator bullishness. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent FDA approval to lift the clinical hold on simufilam for TSC-related epilepsy is a positive development, with Phase 2a trials expected in early 2027.
Outlook remains speculative given negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include ongoing operational losses and dependence on clinical trial success. The stock presents high-risk biotech opportunity with potential upside from successful drug development.
HAFN trades at $10.85, down 0.64% on the day, with a neutral technical signal. The company shows strong fundamentals, with a P/E of 8.35 and net income margin of 24.7%. Recent earnings have consistently beaten expectations, and analysts maintain a 100% buy rating. Key developments include a CEO transition and strategic acquisitions.
Outlook is positive due to robust profitability and growth projections, with 2026 revenue expected to reach $2.7B. Risks include market volatility and execution of new strategies. The stock presents a value opportunity with upside potential, supported by strong cash flow and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Hafnia Limited Common Shares
Hafnia Limited owns and operates a fleet of product and chemical tankers that transport refined oil products, vegetable oils, and chemicals for oil and chemical companies worldwide, across the Long Range, Medium Range, and Handy tanker segments, headquartered in Singapore.
Read more on HAFN →
